ADR BioMedical Holdings is trading on buy orders. The company announced on the 6th that the insurance coverage application process for its medical device for treating male stress urinary incontinence, the Selution Cell Therapy Kit SUI, has advanced to review by the specialized subcommittee on insurance medical materials of the Central Social Insurance Medical Council. This product is a medical device that uses regenerative cells derived from autologous adipose tissue, and has already obtained domestic manufacturing and marketing approval. It was approved following deliberation at the insurance coverage committee held in June. The impact on consolidated results for the fiscal year ending March 2027 is currently under review.
ADR Biomedical Holdings Inc.Insurance coverage application for Selution Cell Therapy Kit SUI advanced to subcommittee review, a positive regulatory step toward reimbursement.